Abeona Therapeutics (ABEO) Cash from Investing Activities (2011 - 2026)

Abeona Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 17.8% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $105.8 million (up 488.75% YoY), while the FY2025 annual figure was $105.0 million, up 367.66% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $5.0 million, down from $9.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $155.9 million in Q2 2025, with the low at -$64.6 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $1.6 million (2022), against an average of $2.8 million.
• Peak annual rise in Cash from Investing Activities reached 472.75% in 2023, while the deepest fall reached 1236.63% in 2023.
• Abeona Therapeutics' Cash from Investing Activities stood at -$25.3 million in 2022, then jumped by 145.59% to $11.5 million in 2023, then soared by 63.73% to $18.9 million in 2024, then sank by 49.39% to $9.6 million in 2025, then tumbled by 48.05% to $5.0 million in 2026.
• Business Quant data shows ABEO's Cash from Investing Activities at $5.0 million in Q1 2026, $9.6 million in Q4 2025, and -$64.6 million in Q3 2025.